Published in Cancer Weekly, October 28th, 2003
The electronic submission was produced in an internationally agreed upon format that facilitates regulatory review in the United States, Europe and Japan. The submission is taking place on a "rolling" basis, which allows Allos to submit portions of the NDA as they are completed.
The first part of the application containing non-clinical information was submitted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.